INNOVIVA, INC. Number of Reportable Segments
INNOVIVA, INC. (INVA) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-05
- INNOVIVA, INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- INNOVIVA, INC. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
- INNOVIVA, INC. number of reportable segments for fiscal 2024 was 1.00 Segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-06 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |